These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 33018174)

  • 41. Abnormal organization of white matter networks in patients with subjective cognitive decline and mild cognitive impairment.
    Wang XN; Zeng Y; Chen GQ; Zhang YH; Li XY; Hao XY; Yu Y; Zhang M; Sheng C; Li YX; Sun Y; Li HY; Song Y; Li KC; Yan TY; Tang XY; Han Y
    Oncotarget; 2016 Aug; 7(31):48953-48962. PubMed ID: 27418146
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Altered pattern analysis and identification of subjective cognitive decline based on morphological brain network.
    Xu X; Chen P; Xiang Y; Xie Z; Yu Q; Zhou X; Wang P
    Front Aging Neurosci; 2022; 14():965923. PubMed ID: 36034138
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effective and Accurate Diagnosis of Subjective Cognitive Decline Based on Functional Connection and Graph Theory View.
    Xu X; Li W; Tao M; Xie Z; Gao X; Yue L; Wang P
    Front Neurosci; 2020; 14():577887. PubMed ID: 33132832
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Which features of subjective cognitive decline are related to amyloid pathology? Findings from the DELCODE study.
    Miebach L; Wolfsgruber S; Polcher A; Peters O; Menne F; Luther K; Incesoy E; Priller J; Spruth E; Altenstein S; Buerger K; Catak C; Janowitz D; Perneczky R; Utecht J; Laske C; Buchmann M; Schneider A; Fliessbach K; Kalbhen P; Heneka MT; Brosseron F; Spottke A; Roy N; Teipel SJ; Kilimann I; Wiltfang J; Bartels C; Düzel E; Dobisch L; Metzger C; Meiberth D; Ramirez A; Jessen F; Wagner M
    Alzheimers Res Ther; 2019 Jul; 11(1):66. PubMed ID: 31366409
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of radiomic features and support vector machine to discriminate subjective cognitive decline and healthy controls
    Wu Y; Li T; Han Y; Jiang J
    Annu Int Conf IEEE Eng Med Biol Soc; 2020 Jul; 2020():1762-1765. PubMed ID: 33018339
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A novel joint HCPMMP method for automatically classifying Alzheimer's and different stage MCI patients.
    Sheng J; Wang B; Zhang Q; Liu Q; Ma Y; Liu W; Shao M; Chen B
    Behav Brain Res; 2019 Jun; 365():210-221. PubMed ID: 30836158
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.
    Khosravi M; Peter J; Wintering NA; Serruya M; Shamchi SP; Werner TJ; Alavi A; Newberg AB
    J Alzheimers Dis; 2019; 70(4):1197-1207. PubMed ID: 31322568
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Altered Patterns of Phase Position Connectivity in Default Mode Subnetwork of Subjective Cognitive Decline and Amnestic Mild Cognitive Impairment.
    Cai C; Huang C; Yang C; Zhang X; Peng Y; Zhao W; Hong X; Ren F; Hong D; Xiao Y; Yan J
    Front Neurosci; 2020; 14():185. PubMed ID: 32265623
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Disrupted morphological brain network organization in subjective cognitive decline and mild cognitive impairment.
    Chen Y; Liang L; Wei Y; Liu Y; Li X; Zhang Z; Li L; Deng D
    Brain Imaging Behav; 2024 Apr; 18(2):387-395. PubMed ID: 38147273
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Use of multilayer network modularity and spatiotemporal network switching rate to explore changes of functional brain networks in Alzheimer's disease.
    Yang F; Li Y; Han Y; Jiang J
    Annu Int Conf IEEE Eng Med Biol Soc; 2020 Jul; 2020():1104-1107. PubMed ID: 33018179
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Brain [18F]FDDNP binding and glucose metabolism in advanced elderly healthy subjects and Alzheimer's disease patients.
    Tauber C; Beaufils E; Hommet C; Ribeiro MJ; Vercouillie J; Vierron E; Mondon K; Cottier JP; Gissot V; Guilloteau D; Camus V
    J Alzheimers Dis; 2013; 36(2):311-20. PubMed ID: 23609763
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A FDG-PET Study of Metabolic Networks in Apolipoprotein E ε4 Allele Carriers.
    Yao Z; Hu B; Zheng J; Zheng W; Chen X; Gao X; Xie Y; Fang L;
    PLoS One; 2015; 10(7):e0132300. PubMed ID: 26161964
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Alzheimer Disease and Mild Cognitive Impairment: Integrated Pulsed Arterial Spin-Labeling MRI and
    Riederer I; Bohn KP; Preibisch C; Wiedemann E; Zimmer C; Alexopoulos P; Förster S
    Radiology; 2018 Jul; 288(1):198-206. PubMed ID: 29762090
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of APOEε4 on Functional Brain Network in Patients with Subjective Cognitive Decline: A Resting State Functional MRI Study.
    Deng S; Sun L; Chen W; Liu X; Chen S
    Int J Gen Med; 2021; 14():9761-9771. PubMed ID: 34934350
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anosognosia Is an Independent Predictor of Conversion From Mild Cognitive Impairment to Alzheimer's Disease and Is Associated With Reduced Brain Metabolism.
    Gerretsen P; Chung JK; Shah P; Plitman E; Iwata Y; Caravaggio F; Nakajima S; Pollock BG; Graff-Guerrero A;
    J Clin Psychiatry; 2017; 78(9):e1187-e1196. PubMed ID: 29022655
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cerebrospinal fluid lactate levels and brain [18F]FDG PET hypometabolism within the default mode network in Alzheimer's disease.
    Liguori C; Chiaravalloti A; Sancesario G; Stefani A; Sancesario GM; Mercuri NB; Schillaci O; Pierantozzi M
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2040-9. PubMed ID: 27221635
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Structural integrity in subjective cognitive decline, mild cognitive impairment and Alzheimer's disease based on multicenter diffusion tensor imaging.
    Brueggen K; Dyrba M; Cardenas-Blanco A; Schneider A; Fliessbach K; Buerger K; Janowitz D; Peters O; Menne F; Priller J; Spruth E; Wiltfang J; Vukovich R; Laske C; Buchmann M; Wagner M; Röske S; Spottke A; Rudolph J; Metzger CD; Kilimann I; Dobisch L; Düzel E; Jessen F; Teipel SJ;
    J Neurol; 2019 Oct; 266(10):2465-2474. PubMed ID: 31227891
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer's disease.
    Drzezga A; Altomare D; Festari C; Arbizu J; Orini S; Herholz K; Nestor P; Agosta F; Bouwman F; Nobili F; Walker Z; Frisoni GB; Boccardi M;
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(9):1487-1496. PubMed ID: 29756163
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Age- and Brain Region-Specific Changes of Glucose Metabolic Disorder, Learning, and Memory Dysfunction in Early Alzheimer's Disease Assessed in APP/PS1 Transgenic Mice Using
    Li XY; Men WW; Zhu H; Lei JF; Zuo FX; Wang ZJ; Zhu ZH; Bao XJ; Wang RZ
    Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27763550
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum.
    Tosun D; Schuff N; Jagust W; Weiner MW;
    Neurodegener Dis; 2016; 16(1-2):87-94. PubMed ID: 26560336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.